It’s almost time to see the Sabaat duo reunite on screen! After teasing a project last year with actor Ameer Gilani, Mawra Hocane has now confirmed to star in a drama serial with the Harvard graduate.
However, Ameer has now clarified that contrary to ongoing rumours, the project is titled Neem, and not Nouroz – another upcoming serial of Mawra that publications are mixing with this one.
“It’s a love story at its heart but the larger message is about education – education for everyone in this country,” Ameer told The Express Tribune in a telephonic conversation. The actor revealed that Neem, rallying for the right to education for all, is a little personal for him since he went to finish his education at Harvard after his debut in Sabaat. “Acting is my passion but I had to complete my education. I’m back and I hope I deliver and come through on the expectations that people have from me.”
While Ameer is excited about his comeback to television, the actor revealed that he hadn’t been sitting idle on his passion for the past three years. “The script for Neem has been in the works for about three years. I have rejected about 20-30 scripts to work on this one. I believe in quality work over quantity and this one has an important message.”
The actor said that he “wishes” to speak more about the script that won his heart but cannot reveal much at this time. “You’ll see it soon. Neem will be shot in Kashmir and Mawra Hocane is the female protagonist. It also stars Syed Jibran and Arsalan Naseer,” he concluded.
Mawra reshared a news article boasting about “social media user's favourite couple” returning to screens with smiling emojis on her Instagram Story. Written by Kashif Anwar and produced by Momina Duraid, the romantic social drama will be helmed by famed Parizaad director Shahzad Kashmiri. Mawra and Ameer last shared a screen in the 2020 drama serial Sabaat, also penned by Anwar.
COMMENTS
Comments are moderated and generally will be posted if they are on-topic and not abusive.
For more information, please see our Comments FAQ